No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa1034
Abstract: Introduction: Anaphylaxis and severe hypersensitivity reactions are a concern for any biologic substance. The anti-IL-13 agent tralokinumab is produced by a murine cell line and may thus incorporate immunogenic α-Gal epitopes in the Fab domain.… read more here.
Keywords: clinical studies; severe hypersensitivity; gal epitopes; hypersensitivity reactions ... See more keywords